Comments
Natco Pharma has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets used for the treatment of chronic hepatitis C in India.
The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name ‘Velpanat’, Natco Pharma said in a BSE filing today.
The company’s product is a generic version of Gilead Sciences Inc’s Epclusa tablets.
Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis, Natco Pharma said.
Natco Pharma has priced its generic tablets at an MRP of Rs 18,500 for a bottle of 28 tablets in India, the company said.
The company “has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.
Shares of Natco Pharma were trading up by 0.63 per cent at Rs 907.25 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.